Sparrow A, Geelhoed G
Emergency Department, Princess Margaret Hospital for Children, Perth, Western Australia, Australia.
Arch Dis Child. 2006 Jul;91(7):580-3. doi: 10.1136/adc.2005.089516. Epub 2006 Apr 19.
Croup remains a common respiratory problem presenting to emergency departments. A single oral treatment of oral dexamethasone results in improved outcome. Prednisolone has similar pharmacokinetic properties and has a significant advantage in that it is commercially available in liquid preparations.
To ascertain whether a single oral dose of prednisolone was equivalent to a single oral dose of dexamethasone (matched for potency) in children with mild to moderate croup.
A double blind, randomised, controlled equivalence trial.
Tertiary paediatric emergency department.
133 children aged 3 to 142 months presenting with mild to moderate croup.
Children received either a single oral dose of dexamethasone 0.15 mg/kg or single oral dose of prednisolone 1 mg/kg.
The main outcome measure was unscheduled re-presentation to medical care as determined by telephone follow up at 7 to 10 days. Croup score, adrenaline (epinephrine) use, time spent in the emergency department, and duration of croup and viral symptoms were secondary outcome measures.
Children treated with prednisolone were more likely to re-present: 19 of 65 children (29%) reattended medical care compared with 5 of 68 (7%) from the dexamethasone group. The confidence intervals around this 22% difference in outcome were 8% to 35%, outside the 0% to 7.5% range of equivalence. There were no significant differences in other outcome measures.
A single oral dose of prednisolone is less effective than a single oral dose of dexamethasone in reducing unscheduled re-presentation to medical care in children with mild to moderate croup.
哮吼仍是急诊科常见的呼吸道问题。单次口服地塞米松治疗可改善预后。泼尼松龙具有相似的药代动力学特性,且其显著优势在于有液体制剂可供商业使用。
确定单次口服泼尼松龙对轻度至中度哮吼患儿的疗效是否等同于单次口服(效价匹配的)地塞米松。
双盲、随机、对照等效性试验。
三级儿科急诊科。
133名年龄在3至142个月之间的轻度至中度哮吼患儿。
患儿接受单次口服0.15毫克/千克地塞米松或单次口服1毫克/千克泼尼松龙。
主要结局指标是通过7至10天的电话随访确定的非计划再次就医情况。哮吼评分、肾上腺素使用情况、在急诊科的停留时间以及哮吼和病毒症状的持续时间为次要结局指标。
接受泼尼松龙治疗的患儿更有可能再次就医:65名患儿中有19名(29%)再次就医,而地塞米松组68名患儿中有5名(7%)再次就医。这一22%的结局差异的置信区间为8%至35%,超出了0%至7.5%的等效范围。其他结局指标无显著差异。
对于轻度至中度哮吼患儿,单次口服泼尼松龙在减少非计划再次就医方面的效果不如单次口服地塞米松。